{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:07:50Z","timestamp":1770822470468,"version":"3.50.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T00:00:00Z","timestamp":1242864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutic Advances in Cardiovascular Disease"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:p> CRP levels are strong, independent predictors of cardiovascular risk and can enhance risk stratification. Jupiter enrolled 17 802 apparently healthy middle-aged men and women with CRP levels over 2.0 mg\/l, and LDL less than 130 mg\/dl. They were randomized to receive rosuvastatin 20 mg daily or placebo, and followed for a primary endpoint of nonfatal myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death for 1.9 years. Rosuvastatin lowered CRP (37%), LDL (50%), nonfatal myocardial infarction (55%), nonfatal stroke (48%), hospitalization and revascularization (47%), all-cause mortality (20%), and benefited women and minority subgroups. Rosuvastatin was tolerated relatively well, with a small rise in physician-reported diabetes. Jupiter data suggest that patients with high levels of CRP should receive statins. Approximately 4.3% of the population satisfies Jupiter inclusion criteria. A review of the assessment of cardiovascular risk is under way at the National Institutes of Health to guide practitioners. <\/jats:p>","DOI":"10.1177\/1753944709337056","type":"journal-article","created":{"date-parts":[[2009,5,22]],"date-time":"2009-05-22T00:34:10Z","timestamp":1242952450000},"page":"309-315","source":"Crossref","is-referenced-by-count":18,"title":["The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease"],"prefix":"10.1177","volume":"3","author":[{"given":"Richard","family":"Kones","sequence":"first","affiliation":[{"name":"Cardiometabolic Research Institute, 8181 Fannin St, 314, Houston, TX 77054 USA,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,5,21]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S013"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.04.015"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.02.002"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.6.641"},{"key":"atypb5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1161\/CIRCULATIONAHA.106.178458","volume":"114","author":"Budoff, M.J.","year":"2006","journal-title":"Circulation"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.25.1.16"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.04.018"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.04.019"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-008-0007-2"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.10.002"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1161\/hc4201.097189"},{"key":"atypb13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA..107.181425","volume":"115","author":"Greenland, P.","year":"2007","journal-title":"Circulation"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.147835"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.02.086"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0808320"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-55-1-33"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/47.1.9"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.06.057"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.22.2437"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0216421"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.11.014"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.097360"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000052939.59093.45"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1177\/153857440303700501"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2990"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000100688.17280.E6"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.09.072"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.814251"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000132467.45278.59"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.6.611"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/47.1.28"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1159\/000100908"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-003-0008-z"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.06.054"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055373"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068249"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7141.2008.07770.x"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.831198"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-003-0080-4"}],"container-title":["Therapeutic Advances in Cardiovascular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753944709337056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753944709337056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:29:29Z","timestamp":1740803369000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753944709337056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,21]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1177\/1753944709337056"],"URL":"https:\/\/doi.org\/10.1177\/1753944709337056","relation":{},"ISSN":["1753-9447","1753-9455"],"issn-type":[{"value":"1753-9447","type":"print"},{"value":"1753-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,21]]}}}